Systemic antibacterial activity of novel synthetic cyclic peptides

Antimicrobial Agents and Chemotherapy

Volumn 49, Issue 8, 2005, Pages 3302-3310

  Dartois, Véronique ^a,c   Sanchez Quesada, Jorge ^a,d   Cabezas, Edelmira ^a   Chi, Ellen ^a   Dubbelde, Chad ^a   Dunn, Carrie ^a   Granja, Juan ^a,e   Gritzen, Colleen ^a   Weinberger, Dana ^a   Ghadiri, M Reza ^b   Parr Jr , Thomas R ^a,f  

^a Adaptive Therapeutics Inc   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c NOVARTIS INSTITUTE FOR TROPICAL DISEASES   (Singapore)

^d UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^e UNIVERSITY OF SANTIAGO DE COMPOSTELA   (Spain)

^f Targanta Therapeutics Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPEPTIDE; ISOLEUCYLLEUCYLTRYPTOPHYLHISTIDYLORNITHYLLYSINE; LYSYLLYSYLHISTIDYLLYSYLTRYPTOPHYLLEUCYLTRYPTOPHYLLYSINE; OXACILLIN; RIFAMPICIN; SERYLTRYPTOPHYL O BENZYLTYROSYLLYSYLASPARAGINYLLYSYLSERYLLYSINE; SERYLTRYPTOPHYLPHENYLALANYLLYSYLHISTIDYLLYSYLSERYLLYSINE; SERYLTRYPTOPHYLPHENYLALANYLLYSYLTHREONYLLYSYLSERYLLYSINE; UNCLASSIFIED DRUG; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MEMBRANE; BACTERIAL PERITONITIS; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG EFFICACY; FEMALE; GRAM POSITIVE BACTERIUM; INFECTION; MAXIMUM TOLERATED DOSE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN ASSEMBLY; STAPHYLOCOCCUS AUREUS; STEADY STATE; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTI-BACTERIAL AGENTS; FEMALE; MICE; MICE, INBRED ICR; MICROBIAL SENSITIVITY TESTS; MUSCULAR DISEASES; NEUTROPENIA; PEPTIDE LIBRARY; PEPTIDES, CYCLIC; PERITONITIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; THIGH; TREATMENT OUTCOME;

EID: 23044472138     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.49.8.3302-3310.2005     Document Type: Article

References (39)

1. Alborn, W. E. J., N. E. Allen, and D. A. Preston. 1991. Daptomycin disrupts membrane potential in growing Staphylococcus aureus. Antimicrob. Agents Chemother. 35:2282-2287.
2. Bessalle, R., A. Kapitkovsky, A. Gorea, I. Shalit, and M. Fridkin. 1990. All-D-magainin: chirality, antimicrobial activity and proteolytic resistance. FEBS Lett. 274:151-155.
3. Bong, D. T., T. D. Clark, J. R. Granja, and M. R. Ghadiri. 2001. Self-assembling organic nanotubes. Angew. Chem. Int. Ed. Engl. 40:988-1011.
4. Centers for Disease Control and Prevention. 2002. Staphylococcus aureus resistant to vancomycin-United States. Morbid. Mortal. Wkly. Rep. 51: 565-567.
5. Chen, J., T. J. Falla, H. Liu, M. A. Hurst, C. A. Fujii, D. A. Mosca, J. R. Embree, D. J. Loury, P. A. Radel, C. Cheng Chang, L. Gu, and J. C. Fiddes. 2000. Development of protegrins for the treatment and prevention of oral mucositis: structure-activity relationships of synthetic protegrin analogues. Biopolymers 55:88-98.
6. Clark, T. D., J. M. Buriak, K. Kobayashi, M. P. Isler, D. E. McRee, and M. R. Ghadiri. 1998. Cylindrical beta-sheet peptide assemblies. J. Am. Chem. Soc. 120:8949-8962.
7. Clemons, P. A., A. N. Koehler, B. K. Wagner, T. G. Sprigings, D. R. Spring, R. W. King, S. L. Schreiber, and M. A. Foley. 2001. A one-bead, one-stock solution approach to chemical genetics: part 2. Chem. Biol. 8:1183-1195.
8. Cole, A. M. 2005. Antimicrobial peptide microbicides targeting HIV. Protein Pept. Lett. 12:41-47.
9. Contestabile, R., T. Jenn, M. Akhtar, D. Gani, and R. A. John. 2000. Reactions of glutamate 1-semialdehyde aminomutase with R- and S-enantiomers of a novel, mechanism-based inhibitor, 2,3-diaminopropyl sulfate. Biochemistry 39:3091-3096.
10. Coughlin, S. A., D. W. Danz, R. G. Robinson, K. M. Klingbeil, M. P. Wentland, T. H. Corbett, W. R. Waud, L. A. Zwelling, E. Altschuler, E. Bales, et al. 1995. Mechanism of action and antitumor activity of (S)-10-(2,6-dimethyl-4- pyridinyl)-9-fluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyridol[1,2,3-de]-[1,4] benzothiazine-6-carboxylic acid (WIN 58161). Biochem. Pharmacol. 50:111-122.
11. Craig, W. A., and S. Gudmundsson. 1996. Postantibiotic effect, p. 296-329. In V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. Lippincott, Williams & Wilkins, Baltimore, Md.
12. Craig, W. A., J. Redington, and S. C. Ebert. 1991. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J. Antimicrob. Chemother. 27(Suppl. C):29-40.
13. Diekema, D. J., B. J. BootsMiller, T. E. Vaughn, R. F. Woolson, J. W. Yankey, E. J. Ernst, S. D. Flach, M. M. Ward, C. L. Francisais, M. A. Pfaller, and B. N. Doebbeling. 2004. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin. Infect. Dis. 38:78-85.
14. Emori, T. G., and R. P. Gaynes. 1993. An overview of nosocomial infections, including the role of the microbiology laboratory. Clin. Microbiol. Rev. 23:255-259.
15. Fernandez-Lopez, S., H. S. Kim, E. C. Choi, M. Delgado, J. R. Granja, A. Khasanov, K. Kraehenbuehl, G. Long, D. A. Weinberger, K. M. Wilcoxen, and M. R. Ghadiri. 2001. Antibacterial agents based on the cyclic D,L-alpha-peptide architecture. Nature 412:452-455.
16. Fujimura, S., S. Kato, M. Hashimoto, H. Takeda, F. Maki, and A. Watanabe. 2004. Survey of MRSA from neonates and the environment in the NICU. J. Infect. Chemother. 10:131-132.
17. Furka, A., F. Sebestyen, M. Asgedom, and G. Dibo. 1991. General method for rapid synthesis of multicomponent peptide mixtures. Int. J. Pept. Protein Res. 37:487-493.
18. Ghadiri, M. R., J. R. Granja, and L. K. Buehler. 1994. Artificial transmembrane ion channels from self-assembling peptide nanotubes. Nature 369:301-304.
19. Granja, J. R., and M. R. Ghadiri. 1994. Channel-mediated transport of glucose across lipid bilayers. J. Am. Chem. Soc. 116:10785-10786.
20. Griffith, D. C., L. Harford, R. Williams, V. J. Lee, and M. N. Dudley. 2003. In vivo antibacterial activity of RWJ-54428, a new cephalosporin with activity against gram-positive bacteria. Antimicrob. Agents Chemother. 47:43-47.
21. Jeu, L., and H. B. Fung. 2004. Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin. Ther. 26:1728-1757.
22. Kirby, W. M. 1984. Vancomycin therapy of severe staphylococcal infections. J. Antimicrob. Chemother. 14(Suppl. D):73-78.
23. Kondejewski, L. H., M. Jelokhani-Niaraki, S. W. Farmer, B. Lix, C. M. Kay, B. D. Sykes, R. E. Hancock, and R. S. Hodges. 1999. Dissociation of antimicrobial and hemolytic activities in cyclic peptide diastereomers by systematic alterations in amphipathicity. J. Biol. Chem. 274:13181-13192.
24. Lam, K., S. Salmon, E. Hersh, V. Hruby, W. Kazmierski, and R. Knapp. 1991. A new type of synthetic peptide library for identifying ligand-binding activity. Nature 354:82-84.
25. Lowy, F. D. 1998. Staphylococcus aureus infections. N. Engl. J. Med. 339: 520-532.
26. Nakajima, Y., J. Alvarez-Bravo, J. Cho, K. Homma, S. Kanegasaki, and S. Natori. 1997. Chemotherapeutic activity of synthetic antimicrobial peptides: correlation between chemotherapeutic activity and neutrophil-activating activity. FEBS Lett. 415:64-66.
27. 26a. National Committee for Clinical Laboratory Standards. 2000. M23-A2, vol. 21, no. 7. National Committee for Clinical Laboratory Standards, Wayne, Pa.
28. Peschel, A., M. Otto, R. W. Jack, H. Kalbacher, G. Jung, and F. Gotz. 1999. Inactivation of the dit operon in Staphylococcus aureus confers sensitivity to defensins, protegrins, and other antimicrobial peptides. J. Biol. Chem. 274: 8405-8410.
29. Redman, J. E., K. M. Wilcoxen, and M. R. Ghadiri. 2003. Automated mass spectrometric sequence determination of cyclic peptide library members. J. Comb. Chem. 5:33-40.
30. Reed, L. J., and H. Muench. 1938. A simple method of estimating fifty percent endpoints. Am. J. Hyg. 27:493-497.
31. Sanchez-Quesada, J., M. P. Isler, and M. R. Ghadiri. 2002. Modulating ion channel properties of transmembrane peptide nanotubes through heteromeric supramolecular assemblies. J. Am. Chem. Soc. 124:10004-10005.
32. Schwarz, T. F., S. M. Yeats, P. Connolly, and D. J. McConnell. 1981. Altered transcriptional termination in a rifampicin-resistant mutant of Escherichia coli which inhibits the growth of bacteriophage T7. Mol. Gen. Genet. 183: 181-186.
33. Sista, R. R., G. Oda, and J. Barr. 2004. Methicillin-resistant Staphylococcus aureus infections in ICU patients. Anesthesiol. Clin. N. Am. 22:405-435.
34. Tenover, F. C. 1999. Implications of vancomycin-resistant Staphylococcus aureus. J. Hosp. Infect. 43:S3-S7.
35. Veluri, R., T. L. Weir, H. P. Bais, F. R. Stermitz, and J. M. Vivanco. 2004. Phytotoxic and antimicrobial activities of catechin derivatives. J. Agric. Food Chem. 52:1077-1082.
36. Wade, D., J. Silberring, R. Soliymani, S. Heikkinen, I. Kilpelainen, H. Lankinen, and P. Kuusela. 2000. Antibacterial activities of temporin A analogs. FEBS Lett. 479:6-9.
37. Wellings, D. A., and E. Atherton. 1997. Standard Fmoc protocols. Methods Enzymol. 289:44-67.
38. Yamaoka, K., T. Nakagawa, and T. Uno. 1978. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J. Pharmacokinet. Biopharm. 6:165-175.
39. Zhang, L., and T. J. Falla. 2004. Cationic antimicrobial peptides-an update. Expert Opin. Investig. Drugs 13:97-106.